Fed. Circ. Won't Revive Vanda's Sleep Disorder Patent Claims

Wednesday, May 10, 2023

Cozen O'Connor successfully represented Apotex in a patent dispute with Vanda Pharmaceuticals over the sleep disorder drug Hetlioz. The Federal Circuit upheld a district judge's decision to invalidate four patents owned by Vanda Pharmaceuticals. In January 2023, Cozen O'Connor successfully represented Apotex at the U.S. Court of Appeals for the Federal Circuit in securing a denial of Vanda Pharmaceuticals' bid to seek an injunction pending an appeal of Apotex's and Teva's victory in the District of Delaware. Cozen O'Connor's appellate team included Blake CoblentzAaron Lukas, and Keri Schaubert.

To read more of this article, click here.

Share on LinkedIn


Related Practice Areas

Keep up-to-date with the latest news from Cozen O'Connor

Enter your City or Zip.

Probably shouldn't change this:
Sign up to receive alerts, publications, and event / webinar invites.

By submitting your contact information, you are giving Cozen O'Connor consent to contact you via email.